1. Scrip
  2. >>Therapy Areas
  3. >>Anti-infective

Novartis' MenB vaccine Bexsero set for blockbuster status after new data

 
• By Haylyn Wong

Data presented this week indicate that Novartis's novel meningococcal B vaccine Bexsero has the potential to fill the one unmet need that remains in the meningococcal space – a safe vaccine with broad efficacy against serogroup B infections. Critics have been concerned that Bexsero causes increased rates of fever, but these fears were dampened by additional results presented at the World Vaccines Congress in Washington DC, paving the way for Bexsero to become Novartis's next big blockbuster.

Data presented this week indicate that Novartis's novel meningococcal B vaccine Bexsero has the potential to fill the one unmet need that remains in the meningococcal space – a safe vaccine with broad efficacy against serogroup B infections. Critics have been concerned that Bexsero causes increased rates of fever, but these fears were dampened by additional results presented at the World Vaccines Congress in Washington DC, paving the way for Bexsero to become Novartis's next big blockbuster.

The head of meningococcal vaccines at Novartis, Dr Peter Dull, presented an overview of the Phase III clinical trial results...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anti-infective

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: breaking down big pharma’s executive pay; US vaccine panel upheaval; Merck’s RSV approval; MFN and Japan; and the future of Pfizer and Arvinas’s partnership.

In Brief: Gilead HIV Trials On Hold Over Safety Signal

 
• By Sushmita Panda

The FDA has paused Gilead’s HIV trials of GS-1720 and GS-4182 over safety concerns. The company’s upcoming PrEP PDUFA looks to be unaffected.

In Brief: PolyPid’s D-PLEX100 Aces Phase III Trial, US Partner, Submission Eyed

 
• By Sushmita Panda

PolyPid's D-PLEX100 meets Phase III endpoints this time around, significantly reducing surgical point infections in abdominal colorectal surgery, and is set for a US approval submission early next year.

With ACIP Upheaval, Merck & Co. Among Those Left In A Lurch

 
• By Jessica Merrill and Bridget Silverman

Merck’s newly approved Enflonsia for RSV is one of the products that was expected to be recommended for use by the CDC advisory committee in June.

More from Therapeutic Category

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: breaking down big pharma’s executive pay; US vaccine panel upheaval; Merck’s RSV approval; MFN and Japan; and the future of Pfizer and Arvinas’s partnership.

UroGen Gets A First-Ever Bladder Cancer Approval Despite US FDA AdComm ‘No’ Vote

 
• By Joseph Haas

UroGen’s Zusduri was approved despite an advisory committee vote recommending against it in May. It is the first approved drug for a type of recurring bladder cancer.

UCB Follows Fellow European Pharmas With Major US Investment

 
• By Kevin Grogan

The Belgian drugmaker is boosting its biologics capacity over the pond.